At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
cabozantinibdrug
Likely dose
cabozantinib 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano·interventional·Posted Nov 28, 2017·Updated May 10, 2021
In Brief
A Phase 2 clinical trial evaluating cabozantinib for Collecting Duct Carcinoma (Kidney). Completed, enrolled 23 participants across 1 site.
Detailed Summary
This is a single-arm, phase II trial (monocentric) study designed to determine To evaluate activity of Cabozantinib in terms of ORR according to the RECIST 1.1 criteria in Metastatic Collecting Duct Renal Cell Carcinoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCollecting Duct Carcinoma (Kidney)
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartJan 2018
Primary CompletionNov 2020
TodayJul 2026
First PostedNov 28, 2017
Enrollment StartJan 12, 2018
Primary CompletionNov 19, 2020
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.6 years ago
Interventions
cabozantinibdrug
cabozantinib 60 mg orally once daily